Table 3.

Estimation of malaria attack ( Pv , Pf , all species) during the prophylactic phase (6 month) of Study 033

Data*	Value**	Source
Post deployment P. vivax relapse rate (%) amongst Study 033 subjects	1.23	Pv relapses (8/651) from CMR not original Study 033 FCSR (Equation 1)
Anti-relapse effectiveness (%) of primaquine	69.5	Estimated from John et al. 2012
Anti-relapse efficacy (%) of tafenoquine	86.3	Estimated from Walsh et al. 2004b
Anti-relapse efficacy of combined Study 033 post-exposure prophylaxis regimens	82.1	Estimated (Equation 5)
Pv attack rate (%) during prophylactic phase of Study 033	6.88	Estimated (Equation 7)
Ratio of Pf cases to Pv cases in 1999/2000 ADF deployment (InterFET)	0.146	Observed from 1999/2000 ADF deployment (Equation 4)
Pf attack rate (%) during prophylactic phase of Study 033	1.00	Estimated (Equation 8)
All malaria attack rate (%) during prophylactic phase of Study 033	7.88	Estimated (Equation 6)

*Observed in Study 033, ADF deployment, assumed from literature or derived. **Rounded after calculation.